Who is sponsoring NCT00410787?

NCT00410787 is sponsored by Alza Corporation, DE, USA.

What condition does NCT00410787 study?

NCT00410787 studies Analgesics, Opioid, Pain.

What drugs are being tested in NCT00410787?

Interventions: OROS hydromorphone HCI (slow release).

What is the status of NCT00410787?

NCT00410787 is currently COMPLETED.

Last reviewed 2010-04-26 · How we verify

Safety and Tolerability of Long-Term Administration of Dilaudid SR (Hydromorphone HCI) in Cancer Pain

NCT00410787 Phase 3 COMPLETED

The primary purpose of this study was to characterize the pain control achieved with long-term repeated dosing of OROS hydromorphone (slow release) in patients with chronic cancer pain and the secondary purpose was to characterize the effects of pain on the patients' quality of life with long-term, repeated dosing of OROS hydromorphone (slow release) taken by patients with chronic cancer pain.

Details

Lead sponsor	Alza Corporation, DE, USA
Phase	Phase 3
Status	COMPLETED
Enrolment	68
Completion	2002-04

Conditions

Analgesics, Opioid
Pain

Interventions

OROS hydromorphone HCI (slow release)

Primary outcomes

Study results indicated that long-term treatment with OROS hydromorphone can be useful in the management of persistent, moderate-to-severe chronic pain in patients with cancer